Table 2.

Physical and 2DE structural and functional parameters at baseline

	Level	Parameter	Group
			Control	Empagliflozin
		Body weight [gr]	413 ± 35	395 ± 37
Apical level	Systolic	LVESA [mm2]	16.4 ± 5.9	15.8 ± 5.3
		LVIDs [mm]	4.2 ± 0.7	4.6 ± 0.7
	Diastolic	LVEDA [mm2]	43.3 ± 4.9	39.2 ± 5.4
		LVIDd [mm]	7.6 ± 0.6	7.0 ± 0.6
	Function	FS [%]	39.7 ± 3.9	35.6 ± 3.8
		FAC [%]	63.1 ± 3.7	59.0 ± 3.7
		EF [%]	74.5 ± 6.4	70.4 ± 6.2
Papillary muscles level	Systolic	LVESA [mm2]	20.5 ± 4.3	26.2 ± 4.3
		LVIDs [mm]	4.3 ± 0.6	4.9 ± 0.7
	Diastolic	LVEDA [mm2]	51.2 ± 4.7	47.1 ± 4.6
		LVIDd [mm]	7.5 ± 0.6	7.3 ± 0.5
	Function	FS [%]	36.2 ± 3.1	39.7 ± 3.2
		FAC [%]	52.3 ± 3.6	56.2 ± 4.0
		EF [%]	69.9 ± 5.3	76.4 ± 5.4

LVESA, LVEDA—LV end systolic and end diastolic area, respectively. LVIDs, LVIDd—LV end systolic and end diastolic internal diameter, respectively. FS fractional shortening, FAC fractional area change, EF ejection fraction